Clinical Efficacy of Yishen Qingli Huoxue Xiezhuo Formula in Treating Patients with Chronic Kidney Disease Stages 3-5 and Its Impact on Serum Cytokines
Objective To observe the clinical efficacy of the Yishen Qingli Huoxue Xiezhuo formula in treating patients with chronic kidney disease(CKD)stages 3-5 and its impact on serum cytokines.Methods A total of 89 CKD stage 3～5 patients admitted to the Nephrology Department of Jiangsu Province Hospital of Chinese Medicine from July 2020 to July 2021 were selected.They were divided into a control group(45 cases)and a treatment group(44 cases)using the random number table method.The control group received basic Western medicine treatment,while the treatment group received the Yishen Qingli Huoxue Xiezhuo Formula in addition to the basic treatment.After three months of treatment,clinical efficacy,adverse reactions,the total score of traditional Chinese medicine(TCM)clinical symptoms,kidney-relat-ed indicators[serum creatinine(Scr),blood urea nitrogen(BUN),estimated glomerular filtration rate(eGFR),hemoglobin(Hb),albumin(ALB),24-hour urinary total protein(UTP)],and cytokine levels[interleukin-1β(IL-1β),interleu-kin-2(IL-2),interleukin-4(IL-4),interleukin-10(IL-10),interleukin-12P70(IL-12P70),interleukin-17(IL-17),interferon-γ(IFN-γ),and tumor necrosis factor-α(TNF-α)]were observed and compared before and af-ter treatment.Results After treatment,the total clinical effective rate was significantly higher in the treatment group(84.09％,37/44)compared to the control group(55.56％,25/45),with a statistically significant difference(P＜0.05).Both groups showed a significant decrease in the total score of TCM clinical symptoms after treatment,with a statistically significant difference(P＜0.05);the treatment group showed a significantly lower score than the control group,with a sta-tistically significant difference(P＜0.05).The control group showed significant decreases in BUN,Scr,and UTP levels and a significant increase in Hb level compared to before treatment,with a statistically significant difference(P＜0.05);while eGFR and ALB levels increased compared to before treatment,without a statistically significant difference(P＞0.05).The treatment group showed significant decreases in BUN,Scr,and UTP levels and significant increases in eGFR,ALB,and Hb levels compared to before treatment,with a statistically significant difference(P＜0.05);in the treatment group,BUN,Scr,and UTP levels were significantly lower than in the control group and eGFR,ALB,and Hb levels were significantly higher than in the control group,with a statistically significant difference(P＜0.05).Both groups showed significant reductions in pro-inflammatory cytokines IL-2,IL-12P70,IL-17,IFN-γ,and the fibrosis marker TNF-α,and significant increa-ses in anti-inflammatory cytokines IL-4,IL-5,and IL-10,with a statistically significant difference(P＜0.05);in the treatment group,pro-inflammatory cytokines IL-2,IL-12P70,IL-17,IFN-γ,and the fibrosis marker TNF-α were significantly lower than in the control group,while anti-inflammatory cytokines IL-4,IL-5,and IL-10 were signifi-cantly higher than in the control group,with a statistically significant difference(P＜0.05).No serious drug-related gas-trointestinal symptoms or allergic reactions occurred in either group during treatment.Conclusion The Yishen Qingli Huoxue Xiezhuo formula can effectively improve clinical symptoms,reduce proteinuria,delay renal failure,and regulate pe-ripheral blood inflammation and fibrosis cytokines in patients with CKD stages 3-5,with a high level of safety.
万方数据
维普
